Women who reported recent, regular use of low-dose aspirin (100 milligrams or less) had a 23% lower risk of developing ovarian cancer when compared with women who did not regularly take aspirin, according to new research led by Harvard T.H. … Read more
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.
Visit OCRA's website to read the press release and FAQs about the two organizations coming together and learn about all of the services and programs offered.
If you have other questions or are looking for other information, please contact us at info@ocrahope.org